Multiplatform molecular profiling of 2,400 pancreatic adenocarcinomas to identify targets for therapeutic intent


Sherri Z. Millis, PhD, David Arguello, MD, Maeve A. Lowery, MD, Eileen M. O'Reilly, MD


Pancreas adenocarcinoma (PC) is a challenging disease with overall single digit 5-year survivorship. Few validated biomarkers exist for directing treatment in PC. Only one targeted agent (erlotinib) is FDA approved and was developed in an unselected population (Moore, et al, J Clin Oncol, 2007). Identification of individual PC genomic and phenotypic profiles may yield targets with novel therapeutic application.

Download Publication